This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidneydisease (CKD) and other diseases, hasannounced that the U.S. The primary outcome measure is absolute change in the frequency of apnea-hypopnea episodes. tim.hodson Wed, 01/08/2025 - 14:11 Jan.
Hypertension, Ahead of Print. BACKGROUND:Intensive blood pressure (BP) control in youth with chronic kidneydisease (CKD) slows progression, delaying the need for kidney replacement therapy (KRT). Most youth with CKD have hypertension and BP control is difficult to achieve outside of controlled experimental settings.
Hypertension, Volume 80, Issue 12 , Page 2533-2543, December 1, 2023. BACKGROUND:Hypertension frequently accompanies chronic kidneydisease (CKD) as etiology and sequela. We defined CKD as a sustained estimated glomerular filtration rate value <60 mL/min per 1.73 m2or a urine albumin-to-creatinine ratio ≥30 mg/g.
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidneydisease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
Indeed, numerous studies are currently investigating the impact of such approaches on clinical outcomes and healthcare utilisation. Accordingly, the management of AF has shifted towards a holistic and integrated approach, targeting comorbidities and risk factors, itself associated with improved outcomes. 2 Before the. 2 Before the.
Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidneydisease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.
Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidneydisease. Michos, MD, MHS, FACC, FAHA, FASE, FASPC ; famed hypertension expert Keith C.
The primary outcome was a composite of inhospital adverse events. Associations between multimorbidity patterns and outcomes were evaluated using multivariableadjusted logistic regression models. years]) admitted to the China Chest Pain Center Database between 2016 and 2021. Among 9570 patients, 50% (n=4789) had multimorbidity.
This study evaluates the outcomes in patients admitted for HF with and without hyperkalemia.Methods:We used the Nationwide Readmissions Database (NRD) from 2016-2019, extracting adult patients with a primary diagnosis of HF who were admitted between January and November of each year. vs. 2.5%, p < 0.001). 2], p<0.001).Conclusion:Hyperkalemia
Evaluate the benefit in important cardiovascular outcomes and safety in elderly patients of a blood pressure control ≤ 130mmHg compared to standard of care.Methods:The research was performed in PubMed, EMBASE, Scielo, LILACS, and Cochrane Central Register of Controlled Trials (CENTRAL) from January 1st, 2013 to May 1st, 2023.
Propensity score-matched analysis (PSM) (1:1) was performed on age, gender, BMI, hypertension, diabetes mellitus, chronic kidneydisease, hemoglobin level, LDL level, left ventricular ejection fraction and various drugs including beta blockers, ACEi and ARBi.
vs 63.38, p<0.001) and had fewer comorbidities such as cancer and chronic kidneydisease, atrial fibrillation, hypertension, hyperlipidemia. We observed an increasing trend of ICH among pregnant individuals. Pregnant patients were notably younger (30.63 vs 16.2%, p<0.001). vs 23.2%, p<0.001).
Objectives We aim to assess the association of cardiovascular medications with outcomes of patients referred to the diagnostic heart failure (HF) clinic with symptoms or signs of possible HF, raised N-terminal pro-brain-type natriuretic peptide (NT-proBNP) but no evidence of HF on transthoracic echocardiography (TTE). to 0.97; p=0.02).
Background Preeclampsia (PE) is associated with subsequent higher risk of cardiovascular and kidneydisease. Serum copeptin, as a proxy for vasopressin, and urinary uromodulin, were associated with PE physiopathology and kidney functional mass respectively.
Propensity score-matched analysis (PSM) (1:1) was performed with matching for age, gender, race, BMI, hypertension, diabetes mellitus, chronic kidneydisease, hemoglobin level, low-density lipid (LDL) level, left ventricular ejection fraction, and various drugs including ACEi, ARBi, ARNI, beta-blockers, and diuretics.
Abstract Aims Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy that commonly presents with concomitant chronic kidneydisease. Albuminuria is common in heart failure and associated with worse outcomes, but its prevalence and relationship to outcome in ATTR-CA remains unclear.
The primary exposure variable was 5-HTP levels, and the primary outcome was the severity of coronary calcification assessed through fluoroscopy. to 1.63); hypertension 1.57 (0.87 to 2.31); chronic kidneydisease 1.07 (0.33 High 5-HTP levels were significantly associated with more severe calcification (p = 0.04, OR = 3.3,
BackgroundClinical outcome of ischemic cardiogenic shock (CS) requiring extracorporeal membrane oxygenation is highly variable, necessitating appropriate assessment of prognosis. Journal of the American Heart Association, Ahead of Print. However, a systemic predictive model estimating the mortality of refractory ischemic CS is lacking.
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidneydisease, diabetes and obesity. The virtual, self-paced Foundations of Cardiometabolic Health Certificate Course is the first step to attaining the CCHP credential.
We compared demographics, hospital traits, comorbidities, and outcomes. In-hospital mortality, our primary outcome, was analyzed through multivariate logistic regression using STATA 18.Results:Incorporating to 2.26) and liver disease (OR 2.20, p < 0.01, CI 1.27
Hypertension, diabetes, hyperlipidemia, and chronic kidneydisease are well-known cardiovascular risk factors for ICH. Stroke, Volume 56, Issue Suppl_1 , Page A49-A49, February 1, 2025. Introduction:Intracranial hemorrhage (ICH) is the most severe adverse effect of anticoagulation in atrial fibrillation (AF) patients.
The BACKBEAT pivotal study will evaluate the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), for the treatment of pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications. Orchestra BioMed and Medtronic, Inc. Kowal, M.D., and Europe.
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidneydisease (CKD). In fact, a 2024 report on heart failure trends and outcomes published in the Journal of Cardiac Failure showed that in patients with heart failure with preserved ejection fraction, 5-year mortality was 75.7%.
Background Hypertension is a risk factor for bleeding events and is included in the HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/Alcohol concomitantly) score.
milla1cf Fri, 06/28/2024 - 19:07 June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa , its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs), including chronic kidneydisease (CKD) as well as hypertension and cardiovascular disease.
BackgroundBoth nighttime systolic blood pressure and pulse rate are associated with adverse outcomes in patients with chronic kidneydisease (CKD). Cox regression was used to explore the association between nighttime DP and adverse outcomes.
Bakris , an internationally recognized and influential nephrologist and hypertension expert, who passed away on June 15, 2024, at the age of 72. Bakris’s distinguished career in medicine spanned over four decades, marked by significant contributions to the fields of diabetic kidneydisease, hypertension, and nephropathy progression.
A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. million U.S. adults, according to new estimates from University of California-San Francisco. Earlier projections had estimated that 3.3
Introduction:Chronic kidneydisease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH. For each patient, eGFR along with age, sex, race, ethnicity, hypertension, diabetes (DM), heart disease, and hyperlipidemia were abstracted.
This blog post explores the development of such partnerships and their potential to transform healthcare outcomes. Engaging individuals as active participants in their care plans can significantly enhance outcomes and improve overall quality of life. Key contributions: Advanced cardiac imaging (e.g.,
Introduction:Chronic kidneydisease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH. For each patient, eGFR (estimated glomerular filtration rate) along with age, sex, race, ethnicity, hypertension (HTN), diabetes (DM), heart disease, and hyperlipidemia were abstracted.
This study aimed to identify predictors of worse clinical outcome after deferral of non-emergency cardiovascular interventions. Arterial hypertension (HR 2.27; 95% CI 1.00 to 5.12; p=0.049), chronic kidneydisease (HR 1.89; 95% CI 1.03 to 3.49; p=0.041) as well as severe valvular heart disease (HR 3.08; 95% CI 1.68
We studied incidence, outcomes and temporal trends following PCI-related coronary artery perforation (CAP). Perforation risk factors derived using meta-regression were female sex, hypertension, chronic kidneydisease and previous coronary bypass grafting.
New guidelines also: Classify “Elevated BP” between non-elevated BP and hypertension. Measuring eGFR and albuminuria is recommended for assessing kidneydisease in all hypertensive patients. Advise increased potassium intake for hypertensive patients. Watch here! Read the published study.
Join us as we examine the landmark approvals that are revolutionizing patient outcomes. Notes: Approved after initial rejection two years prior based on safety data from Japan, where the drug had been used since 2020 It can only be used in kidneydisease patients on dialysis for at least 3 months.
Background:Patients with adult congenital heart disease (ACHD) form a unique subset of patients with complex ventricular tachycardia (VT).Objective:To The primary composite outcome was recurrent monomorphic VT, and repeat ablation.Results:Out of 508 procedures for ventricular tachycardia ablation, 37 were performed in ACHD patients.
Prevalence of hypertension (86.6%), heart failure (22.7%), diabetes (54.8%), chronic kidneydisease (23.6%), and chronic obstructive pulmonary disease (35.4%) was high. Ongoing studies will yield important insights regarding improving care and outcomes in this highrisk group. At 1 year, 9.4% of patients had died.
A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. million U.S. adults, according to new estimates from University of California-San Francisco. Earlier projections had estimated that 3.3
Abstract Objectives This study aimed to assess the impact of anemia and iron deficiency (ID) on clinical outcome in patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI). Nevertheless, data concerning the impact of anemia and ID on clinical outcome in patients with CS are scarce.
Background and Purpose:Chronic kidneydisease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025. female, 22.1%
Outcomes included favorable disposition (discharged to home) and in-hospital mortality.Results:Among 68,975 of stroke MT with recorded NIHSS during the study period (51.1% Outcomes included favorable disposition (discharged to home) and in-hospital mortality.Results:Among 68,975 of stroke MT with recorded NIHSS during the study period (51.1%
Because CMHC is committed to forging relationships with organizations that share a pursuit of bettering patient outcomes through unparalleled provider education, many like-minded regional and national organizations will be in attendance.
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Liraglutide and cardiovascular outcomes in type 2 diabetes.” Neal, Bruce, et al. 2017): 644-657. 2016): 311-322.
Participating in any resistance training is associated with a 15%–17% lower risk for these outcomes compared to non-participation. Most data suggest that 30–60 minutes per week is sufficient to maximize the risk reduction — benefits start to plateau and then reverse after this threshold.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content